Integrative Analysis of Large-cell Lung Cancer

Recruiting

• Conditions: Lung Cancer

• Registration Number: NCT02917369
• Lead Sponsor: Shanghai 10th People's Hospital

Brief Summary

Integrative analysis of LCLC

Detailed Description

The investigators will analyzed proteomes of paired normal lung tissues and LCLC with or without liver metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary LCLC carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Study Timeline

• Study Start: 2016-01
• Status Verified: 2016-09
• Study First Submitted: 2016-09-27
• Study First Submitted QC: 2016-09-27
• Last Update Submitted: 2016-09-27
• Study First Posted: 2016-09-28
• Last Update Posted: 2016-09-28
• Primary Completion: 2026-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Age ≤ 75 years with histologically proven LCLC
• No severe major organ dysfunction
• World Health Organization (WHO) performance status of 0 or 1
• No prior cancer chemotherapy

Exclusion Criteria

• Age ≥ 76
• Severe major organ dysfunction
• WHO performance status of >1
• Prior cancer chemotherapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
5 years overall survival	5 years

Secondary Outcome Measures

Name	Time	Method
5 years disease-free survival	5 years

Trial Locations

Locations (3)

Ganzhou City People's Hospital; 🇨🇳 Ganzhou, Jiangxi, China

Shanghai Tenth People's Hospital; 🇨🇳 Shanghai, Shanghai, China

Shanghai Pulmonary Hospital; 🇨🇳 Shanghai, Shanghai, China